Multi-Target Mechanism of Compound Qingdai Capsule for Treatment of Psoriasis: Multi-Omics Analysis and Experimental Verification
Open Access
- 1 June 2025
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 5209-5230
Abstract
Background: Psoriasis is a chronic skin disease affected by genetic and autoimmunity. The traditional Chinese medicine, Compound Qingdai Capsule (CQC), has shown potential benefits in treating psoriasis in clinical settings. Despite its efficacy, the molecular mechanisms underpinning its therapeutic action remain unclear. Purpose: This study aimed to unravel the molecular mechanism of Compound Qingdai Capsule for psoriasis based on the psoriasis pathogenic pathway network, integrating multi-omics analysis, systems pharmacology, machine learning modeling, and animal experimentation. Methods: Psoriasis pathogenic pathway network was constructed through employing bioinformatics analysis and psoriasis-related multi-omics data mining. The ingredients of CQC were detected by UPLC-MS/MS, and target prediction was performed by systems pharmacology. Machine learning, including Lasso regression, Random Forest, and Support Vector Machine (SVM), were utilized to screen core targets of psoriasis. Molecular docking was employed to evaluate the binding affinity between ingredients and core targets. The expression levels of core targets were determined using qRT-PCR and ELISA. Results: Psoriasis-related datasets GSE201827 and GSE174763 were comprehensively analyzed to obtain 635 psoriasis-related genes. These genes were further enriched to elucidate signaling pathways involved, leading to the construction of psoriasis pathogenic pathway network. Utilizing UPLC-MS/MS, 29 main ingredients of CQC were characterized. CQC ingredients-targets network was constructed using these ingredients and their targets. Screening of CQC anti-psoriasis core targets using machine learning algorithm. Molecular docking confirmed good binding affinity between these targets and ingredients. Imiquimod (IMQ) induced psoriasis-like rat validated the anti-psoriasis effect of CQC by alleviating symptoms, reducing spleen and thymus index, and modulating the expressions of core targets at mRNA and protein levels. Conclusion: CQC effectively modulates the expression levels of AURKB, CCNB1, CCNB2, CCNE1, CDK1, and JAK3 through various ingredients, such as astilbin, salvianolic acid A, and engeletin, via multiple pathways, thereby alleviating psoriasis-like symptoms.Keywords
This publication has 48 references indexed in Scilit:
- Outline of Therapeutic Potential of Different Plants Reported Against Psoriasis via In Vitro, Pre‐Clinical or Clinical StudiesPhytotherapy Research, 2025
- Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque PsoriasisJAMA Dermatology, 2024
- Random Forest Modeling of Acute Toxicity in Anal Cancer: Effects of Peritoneal Cavity Contouring Approaches on Model PerformanceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Molecular mechanism of PSORI-CM01 for psoriasis by regulating the inflammatory cytokines networkJournal of Ethnopharmacology, 2023
- Diosmin nanocrystal gel alleviates imiquimod-induced psoriasis in rats via modulating TLR7,8/NF-κB/micro RNA-31, AKT/mTOR/P70S6K milieu, and Tregs/Th17 balanceInflammopharmacology, 2023
- Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S studyJournal of Dermatological Science, 2023
- Multi‐omics integration reveals a core network involved in host defence and hyperkeratinization in psoriasisClinical and Translational Medicine, 2022
- Circ-IGF1R plays a significant role in psoriasis via regulation of a miR-194-5p/CDK1 axisCytotechnology, 2021
- Rosmarinic acid protects mice from imiquimod induced psoriasis‐like skin lesions by inhibiting the IL‐23/Th17 axis via regulating Jak2/Stat3 signaling pathwayPhytotherapy Research, 2021
- Animal models of psoriasis—highlights and drawbacksJournal of Allergy and Clinical Immunology, 2021